Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intranasal bivalent influenza RNA vaccine
- Development stage
- Preclinical
- Lead developer
- Access to Advanced Health Institute
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
The intranasal bivalent influenza RNA vaccine is an investigational vaccine candidate developed by the Access to Advanced Health Institute (AAHI) using its proprietary self-amplifying RNA (saRNA) platform. It is designed to provide protection against pandemic influenza strains A(H5N1) and A(H7N9). The vaccine consists of saRNA that encodes the hemagglutinin (HA) antigens of both strains, formulated within a nanostructured lipid carrier (NLC) optimized for intranasal delivery. This approach is intended to elicit both systemic and mucosal immune responses, potentially offering superior protection at the site of viral entry compared to traditional intramuscular vaccines. The platform is noted for its thermostability at room temperature, which could simplify distribution in resource-limited settings. Preclinical studies have demonstrated efficacy, and the project has received funding from the Medical CBRN Defense Consortium to advance its development.
- Other names
- bivalent H5/H7 saRNA vaccineAAHI bivalent influenza RNA vaccineintranasal bivalent influenza saRNA vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on intranasal bivalent influenza RNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intranasal bivalent influenza RNA vaccine.